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Abstract
Biologics are highly specific and exhibit few problems in regard to overdosages. In clinical practice,
induction schemes with an initial loading dose and a subsequent lower maintenance dose have been
established and are of higher efficacy for psoriasis than starting directly with the maintenance dose. As
obese patients sometimes respond less well to standard dosages, increases of the maintenance dose, but
not the loading doses, have been tried with variable success. In our study, we increased the loading (160
mg instead of 80 mg) but not the maintenance dose of adalimumab in an obese patient with severe
psoriasis resistant to previous biologics and methotrexate. Within 12 weeks, both PASI (11 to 1.6) and
DLQI (22/30 to 5/30) decreased. This strategy might be an effective and less costly alternative to
doubling the maintenance doses, and could be further evaluated for psoriasis patients refractory to
previous treatments.
  




  
 
 
 
 
 
 
 
 
 
 
 
 
